1. 首页
  2. 产品
  3. Signaling Pathways 信号通路
  4. New Products | 新产品
  5. NEW1
  6. New1

Gentamicin sulfate

别名: Gentamicin sulfate; Bristagen; U-Gencin; Gentacidin; Garacin; Garamycin; Gentak; Apogen; NSC-82261; Refobacin; Sch 9724; Gentafair 硫酸庆大霉素;庆大霉素硫酸盐;硫酸艮他霉素;硫酸正泰霉素;硫酸双生霉素;硫酸庆大霉素 标准品;硫酸庆大霉素, usp;硫酸庆大霉素 USP级;硫酸庆大霉素 分析标准品;硫酸庆大霉素盐水合物标准品;硫酸庆大小诺霉素;庆大霉素;庆大霉素硫酸盐 USP标准品;庆大霉素硫酸盐,BC;庆大霉素硫酸酯, USP 级;庆大霉素硫酸;庆大霉素硫酸酯;硫酸庆大酶素;庆大霉素 C;庆大霉素 溶液;硫酸庆大霉素 C1;硫酸庆大霉素
目录号: V17468 纯度: ≥98%
COA 产品数据 产品说明书 SDS
硫酸庆大霉素（Centicin；Refobacin；Septigensulfate；Uuromycine；Oksitselanim；Lyramycin）是一种强效氨基糖苷类抗生素，广泛用于重症监护病房（ICU），用于治疗多种类型的细菌感染，如骨感染、心内膜炎、盆腔炎、脑膜炎、肺炎、尿路感染和败血症等。
Gentamicin sulfate CAS号: 1405-41-0
产品类别: New1
产品仅用于科学研究，不针对患者销售
规格 价格 库存 数量
1g
5g
10g
25g
50g
Other Sizes
加入购物车 结帐 大包装询价
020-31522723 sales@invivochem.cn

Other Forms of Gentamicin sulfate:

  • Gentamicin B
  • Gentamicin/BSA
  • Gentamicin C1a
  • Micronomicin sulfate (硫酸小诺霉素; Gentamicin C2b sulfate; Antibiotic XK-62-2 sulfate; Sagamicin sulfate)
  • 庆大霉素
点击了解更多
InvivoChem产品被CNS等顶刊论文引用
产品描述
硫酸庆大霉素（Centicin；Refobacin；Septigensulfate；Uromycine；Oksitselanim；Lyramycin）是一种强效氨基糖苷类抗生素，广泛用于重症监护病房（ICU），用于治疗多种类型的细菌感染，如骨感染、心内膜炎、盆腔炎、脑膜炎、肺炎、尿路感染和败血症等。它对革兰氏阳性菌和革兰氏阴性菌均具有活性，并且可以抑制组织培养中的多种支原体菌株。庆大霉素还抑制 DNase I，IC50 为 0.57 mM。硫酸庆大霉素是从紫小单孢菌和相关物种中获得的三种不同的密切相关的氨基糖苷硫酸盐（庆大霉素 C1、C2 和 C1(subA)）的复合物。
生物活性&实验参考方法
靶点
Aminoglycoside antibiotic; DNase I (IC50 = 0.57 mM)
体外研究 (In Vitro)
庆大霉素对组织培养单层无害，不影响病毒复制，并且是比青霉素-链霉素联合使用更有效的抗生素激活剂[2]。庆大霉素已被证明对更广泛的生物体（铜绿假单胞菌、变形杆菌属和粪链球菌）具有杀菌作用，并已成功用作真菌学添加剂以限制细菌的生长。生成链霉素和青霉素[2]。庆大霉素在高压灭菌温度下稳定，对恒河猴肾、HeLa 和人羊膜细胞无害，并且不会干扰组织培养中某些脊髓灰质炎病毒和埃可病毒产生的细胞效应 [2]。几种小单孢菌产生庆大霉素[3]。核糖核酸[3]。
体内研究 (In Vivo)
在使用小鼠的感染模型中，硫酸庆大霉素的注射剂和小鼠制剂显示出对鼠疫耶尔森氏菌的强大抗菌活性[3]。用硫酸庆大霉素（0.27 g/kg）治疗的小鼠表现出异物上的细菌显着减少[4]。】。
参考文献

[1]. A rapid and sensitive method for kinetic study and activity assay of DNase I in vitro based on a GO-quenched hairpin probe. Anal Bioanal Chem. 2016 May;408(14):3801-9.

[2]. Antibacterial activity of gentamicin sulfate in tissue culture. Appl Microbiol. 1970 Dec;20(6):989-90.

[3]. Microbial biosynthesis and applications of gentamicin: a critical appraisal.

[4]. Effect of treatment with methicillin and gentamicin in a new experimental mouse model of foreignbody infection. Antimicrob Agents Chemother. 1994 Sep;38(9):2047-53.
其他信息
硫酸庆大霉素是由发酵产生的抗生素复合物的硫酸盐。由三种化学结构密切相关的氨基糖组成。白色至淡黄色粉末。pH值（4%溶液）3.5至5.5。无味。(NTP, 1992) 美国国家毒理学计划，环境健康科学研究所，美国国立卫生研究院 (NTP)。1992。国家毒理学计划化学品库数据库。北卡罗来纳州三角研究园。
硫酸庆大霉素是庆大霉素的硫酸盐形式，庆大霉素是一种广谱氨基糖苷类抗生素复合物，由紫红小单孢菌 (Micromonospora purpurea) 或棘孢小单孢菌 (M. echinospora) 发酵产生，具有抗菌活性。庆大霉素是一种热稳定性复合物，包含庆大霉素C1、C1a、C2、C2a和C2b。硫酸庆大霉素是一种小分子药物，其临床试验阶段最高为IV期（涵盖所有适应症），于1970年首次获批，目前有7项已获批适应症和10项在研适应症。该药物已被美国食品药品监督管理局（FDA）列入黑框警告。它是一种由紫红微单孢菌（Micromonospora purpurea）产生的复杂抗生素物质，包含三种成分：硫酸庆大霉素C1、C2和C1A。
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C24H55N7O11S3*
分子量
561.65 (Average)
精确质量
1487.86917
CAS号
1405-41-0
相关CAS号
Gentamicin;1403-66-3
PubChem CID
9855350
外观&性状
White to off-white solid powder
沸点
797.6ºC at 760 mmHg
熔点
218-237°C
闪点
436.2ºC
tPSA
719.38
氢键供体(HBD)数目
26
氢键受体(HBA)数目
40
可旋转键数目(RBC)
19
重原子数目
101
分子复杂度/Complexity
1930
定义原子立体中心数目
36
SMILES
O=S(O)(O)=O.O[C@]1(C)C(NC)[C@@H](O)[C@@H](O[C@H]2C(N)C[C@H](N)[C@@H](O[C@@H]3[C@H](N)CC[C@@H]([R])O3)[C@@H]2O)OC1.NC[*].C[C@H]([*])N.C[C@H]([*])NC.[R=].[or].[or]
InChi Key
RDEIXVOBVLKYNT-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H43N5O7.C20H41N5O7.C19H39N5O7.H2O4S/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20;1-8(21)12-5-4-9(22)18(30-12)31-15-10(23)6-11(24)16(13(15)26)32-19-14(27)17(25-3)20(2,28)7-29-19;1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17;1-5(2,3)4/h9-20,25-29H,5-8,22-24H2,1-4H3;8-19,25-28H,4-7,21-24H2,1-3H3;8-18,24-27H,3-7,20-23H2,1-2H3;(H2,1,2,3,4)/t9?,10-,11+,12-,13+,14+,15-,16-,17+,18-,19-,20-,21+;8?,9-,10+,11-,12+,13+,14-,15-,16+,17-,18-,19-,20+;8-,9+,10-,11+,12-,13+,14+,15-,16+,17+,18+,19-;/m110./s1
化学名
mixtures of three isomers (Gentamicins C1, C2, and C1(subA).
别名
Gentamicin sulfate; Bristagen; U-Gencin; Gentacidin; Garacin; Garamycin; Gentak; Apogen; NSC-82261; Refobacin; Sch 9724; Gentafair
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

注意： 请将本产品存放在密封且受保护的环境中，避免吸湿/受潮。
运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
H2O : ≥ 30 mg/mL
DMSO :< 1 mg/mL
溶解度 (体内实验)
配方 1 中的溶解度: 100 mg/mL (Infinity mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶。
请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
计算器
计算 重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？
  • 在分子量（MW）框中输入350.26
  • 在“浓度”框中输入10，然后选择正确的单位（mM）
  • 在“体积”框中输入5，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。
计算 重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：
  • 在C1框中输入10，然后选择正确的单位（mM）
  • 在C2框中输入25，然后选择正确的单位（μM）
  • 在V2框中输入25，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案62.5μL（0.1 ml）出现在V1框中
g/mol
计算 重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4  c12h18n3o4
计算化合物摩尔质量（分子量）的说明：
  • 要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义：
  • 分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
  • 摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。
/
计算 重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。
+
+
+
计算 重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。

(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
Aminoglycosides in Early Sepsis
CTID: NCT06712641
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-12-02
Intramedullary Calcium Sulfate Antibiotic Depot
CTID: NCT05766670
Phase: Phase 3    Status: Recruiting
Date: 2024-12-02
Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis
CTID: NCT03132116
Phase: Phase 3    Status: Recruiting
Date: 2024-08-27
Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement
CTID: NCT06489431
Phase: Phase 3    Status: Recruiting
Date: 2024-08-26
Use of Antibiotic Based Irrigation for Ureteroscopic Treatment of Urolithiasis
CTID: NCT06007352
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-07-23
View More

A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia
CTID: NCT04041791
Phase: Phase 3    Status: Completed
Date: 2024-07-08

Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury
CTID: NCT03503513
Phase: Phase 2/Phase 3    Status: Completed
Date: 2024-06-25
Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague
CTID: NCT04110340
Phase: Phase 3    Status: Recruiting
Date: 2024-06-17
The Immunostimulatory Effects of Gentamicin
CTID: NCT05303909
Phase: Phase 2    Status: Terminated
Date: 2024-05-16
Hydrocolloid Dressing for Catheter Exit Site Care in Peritoneal Dialysis Patients
CTID: NCT05143164
Phase: N/A    Status: Active, not recruiting
Date: 2024-05-01
Antibiotic Loaded Cement After TKA
CTID: NCT05429671
Phase: Phase 3    Status: Completed
Date: 2024-04-30
ORal Antibiotics In Acute Mesenteric Ischemia
CTID: NCT06387147
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-04-26
Intravesical Gentamicin to Prevent Recurrent UTI
CTID: NCT06332781
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-03-28
Gentamicin Bladder Instillation on CAUTI
CTID: NCT06332040
Phase: Phase 4    Status: Recruiting
Date: 2024-03-26
Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children
CTID: NCT04876131
Phase: Phase 4    Status: Recruiting
Date: 2024-03-22
Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients
CTID: NCT01785641
Phase: N/A    Status: Completed
Date: 2024-02-21
The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study
CTID: NCT05655689
Phase:    Status: Completed
Date: 2024-01-25
NICU Antibiotics and Outcomes Trial
CTID: NCT03997266
Phase: Phase 4    Status: Recruiting
Date: 2024-01-17
Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery
CTID: NCT03491540
Phase: Phase 3    Status: Completed
Date: 2024-01-05
Gentamicin Open Tibia Study
CTID: NCT05157126
Phase: Phase 4    Status: Recruiting
Date: 2023-12-21
The Safety and Efficacy of Addition of Gentamicin on Irrigation Fluid in Prevention of Post-Transurethral Resection of the Prostate Infectious Complications.
CTID: NCT06168708
Phase: N/A    Status: Recruiting
Date: 2023-12-13
Initial Non-operative Treatment Strategy Versus Appendectomy Treatment Strategy for Simple Appendicitis in Children
CTID: NCT02848820
Phase: Phase 4    Status: Active, not recruiting
Date: 2023-10-23
NICU Antibiotics and Outcomes (NANO) Follow-up Study
CTID: NCT05977400
Phase: Phase 3    Status: Not yet recruiting
Date: 2023-08-04
Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting
CTID: NCT05702762
Phase: Phase 2    Status: Recruiting
Date: 2023-01-27
Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis
CTID: NCT04544943
Phase: Phase 1    Status: Completed
Date: 2022-11-17
Gentamicin Intravesical Efficacy for Infection of Urinary Tract
CTID: NCT04246996
Phase: Phase 2    Status: Completed
Date: 2022-11-08
Efficacy and Comparative of the Association Beclomethasone Clotrimzaol + Gentamicin in Patients With Acne Contaminated
CTID: NCT01244256
Phase: Phase 2/Phase 3    Status: Suspended
Date: 2022-11-03
Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
CTID: NCT03392909
Phase: Phase 1/Phase 2    Status: Unknown status
Date: 2022-11-03
Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery
CTID: NCT03475680
Phase: Phase 3    Status: Terminated
Date: 2022-05-17
Topical Gentamicin Nonsense Suppression Therapy of EB
CTID: NCT04644627
Phase: Phase 1/Phase 2    Status: Completed
Date: 2022-05-03
Vestibular Rehabilitation With Intratympanic Drug Therapy in Meniere's Disease
CTID: NCT05355610
Phase: N/A    Status: Unknown status
Date: 2022-05-02
Gentamicin Bladder Instillation in Individuals With Spinal Cord Injury Having Chronic Urinary Tract Infections
CTID: NCT03931408
Phase: Phase 2    Status: Active, not recruiting
Date: 2022-03-03
Effects of Topical Gentamicin on the Prevention of Peritoneal Dialysis Related Infection
CTID: NCT05251584
Phase: N/A    Status: Unknown status
Date: 2022-02-22
Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition
CTID: NCT05051163
Phase: Phase 2/Phase 3    Status: Unknown status
Date: 2021-09-30
Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)
CTID: NCT04132115
Phase:    Status: Unknown status
Date: 2021-07-21
Evaluation of the Efficacy of Prophylactic Topical Gentamicin in Tunnelled Catheters for Hemodialysis
CTID: NCT04967859
Phase: Phase 1    Status: Completed
Date: 2021-07-20
Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous
CTID: NCT01429701
Phase: Phase 3    Status: Completed
Date: 2021-02-24
Innovative Treatments in Pneumonia (ITIP) 3
CTID: NCT02960919
Phase:    Status: Completed
Date: 2021-02-21
A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome
CTID: NCT02477423
Phase: N/A    Status: Completed
Date: 2020-10-08
Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function
CTID: NCT02415257
Phase: Phase 4    Status: Withdrawn
Date: 2020-09-11
Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens
CTID: NCT03560232
Phase: Phase 4    Status: Terminated
Date: 2020-09-11
Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function
CTID: NCT02379754
Phase: Phase 4    Status: Withdrawn
Date: 2020-09-11
Pharmacokinetics of an Aminoglycoside in Hemodialysis Patients.
CTID: NCT01982864
Phase: Phase 4    Status: Terminated
Date: 2020-07-17
First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition
CTID: NCT03174236
Phase: Phase 3    Status: Unknown status
Date: 2020-05-19
Gentamicin for Junctional Epidermolysis Bul
Short course antibiotic treatment of Gram-negative bacteremia: A multicenter, randomized, non-blinded, non-inferiority interventional study
CTID: null
Phase: Phase 4    Status: Trial now transitioned
Date: 2020-02-11
Assessment of vertigo control rate following common treatments in
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2020-01-22
Impact of topical antibiotic prophylaxis with Gentamicin on SSI rate on elective incisional hernia surgery: a randomised clinical trial.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2020-01-14
Short-course antibiotic regimen compared to conventional antibiotic treatment for gram-positive cocci infective endocarditis: randomized clinical trial
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2019-12-10
The effect of antibiotic eye drops on the nasal microbiome in healthy subjects
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2019-04-25
Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2019-01-14
Pharmacokinetics of different antibiotics in cerebrospinal fluid in children with malignant brain tumors – a pilot study
CTID: null
Phase: Phase 1    Status: Ongoing
Date: 2018-09-27
Pharmacokinetics of antibiotics in cerebrospinal fluid of children with external ventricular drain
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2018-09-27
Development of intravascular microdialysis as a tool for therapeutic drug monitoring in children.
CTID: null
Phase: Phase 1    Status: Prematurely Ended
Date: 2018-03-20
Préparation colique et antibiotiques oraux avant chirurgie du cancer colique: un essai randomisé multicentrique en double aveugle
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2018-03-07
Shorter treatment of catheter related urinary tract infections
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2018-03-07
Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacterermia:
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2017-10-19
Antibiotic treatment alone for children with acute appendicitis; a prospective cohort study part of the Antibiotic versus Primary Appendectomy for Children with acute appendicitis; the APAC trial.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-05-18
Initial non-operative treatment strategy versus appendectomy treatment strategy for simple appendicitis in children aged 7-17 years old. APAC study
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-11-10
Interest of Intra-nodal injection of gentamicin for the treatment of suppurated cat scratch disease’s lymphadenitis: a randomized controlled study.
CTID: null
Phase: Phase 2    Status: Trial now transitioned
Date: 2016-11-07
Individualized dosing of aminoglycosides, quinolones and glycopeptide antibiotics in (morbidly) obese patients
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-05-18
Double-blind, randomised clinical study comparing efficacy and safety of Gentamicin 0.1%_Betamethasone 0.05% Ointment (Test) vs. Diprogenta(R) Ointment (Reference) vs. Vehicle in patients with bacterial infected eczema
CTID: null
Phase: Phase 3    Status: Completed
Date: 2015-12-14
Double-blind, randomised clinical study comparing efficacy and safety of Gentamicin 0.1%_Betamethasone 0.05% Cream (Test) vs. Diprogenta(R) Cream (Reference) vs. Vehicle in patients with bacterial infected eczema
CTID: null
Phase: Phase 3    Status: Completed
Date: 2015-10-27
A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination with Systemic Antibiotic Therapy in Diabetic Patients with an Infected Foot Ulcer
CTID: null
Phase: Phase 3    Status: Ongoing, Completed
Date: 2015-07-10
CONTROLING INTESTINAL COLONIZATION OF HIGH-RISK PATIENTS WITH EXTENDED- SPECTRUM BETALACTAMASE PRODUCING ENTEROBACTERIACEAE (ESBL-E) – A RANDOMIZED TRIAL (CLEAR)
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2014-03-10
Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance during the Treatment of Hospitalized Subjects with Pneumonia Requiring Mechanical Ventilation
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2013-11-12
A randomised control trial to determine whether a 5 day course of antibiotics is more clinically and cost effective than a 24 hour prophylactic course for the prevention of surgical site infection following lower limb amputation surgery
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-03-04
Pharmacokinetics of penicillin, ampicillin and gentamicin in near- term and full-term neonates
CTID: null
Phase: Phase 4    Status: Completed
Date: 2012-12-20
EFFICACY, PHARMACOKINETICS AND SAFETY OF MEROPENEM IN INFANTS BELOW 90 DAYS OF AGE (INCLUSIVE) WITH CLINICAL OR CONFIRMED LATE-ONSET SEPSIS: A EUROPEAN MULTICENTER RANDOMISED PHASE III TRIAL
CTID: null
Phase: Phase 3    Status: Completed
Date: 2011-08-25
Etude multicentrique, de non infériorité, randomisée, ouverte, évaluant l’efficacité de deux Durées d’Antibiothérapie (6 semaines versus 12 semaines) dans le Traitement des Infections sur Prothèses Ostéo-articulaires, avec changement prothétique (en 1 temps ou 2 temps long) ou non (lavage articulaire)
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2011-07-26
Pilot Trial: Feasibility of Microdialysis for Pharmacokinetic Studies in Neonatal Patients
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2010-07-28
REACT ON (REscuing ACTivity Of Na-channels) STUDY Study and correction of abnormalities of nonsense mutations in Brugada Syndrome.
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2010-05-03
The use of prophylactic antibiotics for percutaneous K-wires in orthopaedic surgery
CTID: null
Phase: Phase 4    Status: Completed
Date: 2009-11-12
Effectiveness of Transtympanic Steroids in unilateral Ménière's disease: a Randomised Controlled Double-Blind Trial
CTID: null
Phase: Phase 2    Status: Completed
Date: 2009-03-20
Intratympanic gentamicin therapy for M Meniere: a comparison of two regimes
CTID: null
Phase: Phase 3    Status: Completed
Date: 2009-03-09
A Randomized, Controlled, Open-Label Study to Investigate the Safety and Efficacy
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2008-12-16
A Randomized, Controlled, Open-Label Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge (Collatamp® G) Compared to Levofloxacin in Diabetic Patients with a Mild Infection of a Lower Extremity Skin Ulcer
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2008-09-11
Can long term nebulised gentamicin reduce the bacterial burden, break the vicious cycle of inflammation and improve quality of life in patients with bronchiectasis?
CTID: null
Phase: Phase 4    Status: Completed
Date: 2006-02-24
Linezolid vs Vancomycin/Cefazolin in the treatment of hemodialysis patients with catheter-related gram-positive bloodstream infections
CTID: null
Phase: Phase 3    Status: Prematurely Ended, Completed
Date: 2005-04-28

相关产品
联系我们
电话: 020-31522723 传真: 463611831 邮箱: sales@invivochem.cn
获得最新产品资讯、折扣和优惠
姓名
邮箱

InvivoChem的所有产品仅用于作科学研究，不面向患者销售

Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1

 粤公网安备 44011102003439号

联系我们
Home Classify Cart Member